Biocon Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 1 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹69.3K Cr

Biosimilars are expected to scale meaningfully in the second half of FY '27 and into FY '28 with several new product launches supporting growth and operating leverage. Biosimilars revenue expected to scale meaningfully in the second half of FY '27 and onward, driven by new product launches and expanded markets.

From Biocon Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹416

Market Cap

₹69.3K Cr

P/E Ratio

95.3

How does Biocon Ltd rank in Pharmaceuticals & Biotechnology?

Compare Biocon Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Biocon Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr.

Full financials →

📊 Revenue & Sales Performance

→Biosimilars are expected to scale meaningfully in the second half of FY '27 and into FY '28 with several new product launches supporting growth and operating leverage.
→Insulin franchise has crossed $300 million globally and is expected to grow further with expanded capacity coming into play from the second half of FY '27.
→Generic business will see growth supported both by scale-up of existing products and new approvals, leading to margin improvement as utilization of state-of-the-art facilities increases.
→The U.S. biosimilar business share is growing, currently about 40% of total with a long-term stable mix expected between North America (40%), Europe and Japan/Australia (35%), and emerging markets (25%).
→Focus on margin expansion and sustainable profitable growth with no major greenfield capex expected in FY '27; investments mostly behind, allowing focus on execution and operating leverage.
→Pipeline benefits from faster product development due to FDA biosimilar guideline changes reducing R&D costs and accelerating market entry.

📈 Profitability & Margins

→Biosimilars revenue expected to scale meaningfully in the second half of FY '27 and onward, driven by new product launches and expanded markets.
→EBITDA margins likely to improve due to better revenue mix, operating leverage, and capacity utilization, especially in generics and biosimilars.
→Generics business profitability set to improve as newer assets stabilize and capacity utilization increases.
→Operating leverage benefits to accrue progressively, supporting margin expansion and sustained EBITDA growth.
→FY '27 and FY '28 expected to see ramp-up in biosimilars revenue, with significant scale-up from Q3 FY '27 onwards.
→Interest cost savings from debt reduction will improve profitability and cash generation starting FY '27.
→Management advises looking at growth over a broader time frame rather than quarter-on-quarter; expecting steady, profitable growth rather than rapid market share gains.
→Strong product pipeline and regulatory approvals support a confident outlook for EBITDA and profitability expansion in medium term.

See what Biocon Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→The heavy phase of capital investment is largely complete, with major investments behind the company (Page 5).
→Recent doubling of Malaysia capacity for drug substance and drug product; drug product line 2 is being qualified and will be operational soon, drug substance doubling expected by end of FY '26 (Page 15).
→Minor debottlenecking possible at Bangalore; no large greenfield capex needed currently (Page 15).
→Focus going forward is on execution, operating leverage, and profitable scaling rather than large new capital expenditures (Page 19).
→Capital allocation priorities are on sustaining profitable growth and improving utilization rather than significant new capex (Page 19).
→Biosimilars and generics capacity has been set up ahead of demand; margin improvements expected as utilization ramps up (Pages 16, 19).
→No other major capex beyond Malaysia plant mentioned (Page 12).

💰 Fundraising & Capital Structure

→No explicit mention of current or future fundraising through debt or equity is made in the transcript.
→The company highlights that most capital investments and heavy lifting in capex are behind them.
→Focus is on deleveraging and using free cash flow primarily to reduce existing debt.
→Interest cost savings from previous refinancing will benefit profitability and cash generation.
→The company is monitoring its U.S. dollar bonds for potential call but no firm decisions are announced.
→Emphasis is on execution, operating leverage, and value creation rather than raising new capital.
→No large-ticket greenfield expansions planned that would require significant new funding.

See what Biocon Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The provided transcript from Biocon Limited's Q4 FY26 earnings call (pages 2–22) does not explicitly mention or provide details on the current or expected order book or pending orders. The discussion focuses on topics such as biosimilar sales breakdown, product portfolios, capacity utilization, financial performance, capital allocation, debt reduction, product launches, and market strategy. - No specific data on current order book or pending orders disclosed. - Emphasis on biosimilar portfolio growth and capacity expansion. - Investment focus shifting from capital expenditure to execution and profitable growth. - Discussions centered around market shares, product launches, and revenue growth. If you need detailed order book data, it may be available in the company’s official quarterly or annual reports or investor presentations outside this transcript.

Key Metrics

How does Biocon Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Biocon Ltd

See full Pharmaceuticals & Biotechnology sector rankings

What BIOCON's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
SAIPARENT (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Biocon Ltd Q4 FY26 results?

What is Biocon Ltd share price analysis?

Biocon Ltd currently shows a neutral. The stock trades at a P/E of 95.3 with a market cap of ₹69,295 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon Ltd planning capital expenditure?

The heavy phase of capital investment is largely complete, with major investments behind the company (Page 5).

Keep Biocon Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.